TechLink
While Rus and Tegla received the patent, ”both inventors assigned their patent rights to the University of Maryland-Baltimore, which is the patent’s co-assignee with the VA. But then the university assigned all of its rights to the VA. All that means is that ownership is consolidated now under the VA,” TechLink Senior Technology Manager Gary Bloomer told U.S. Medicine.
“Our marketing on the MS biomarker technology is in progress and is aimed at helping the VA find the best industry partner to take the technology to market, and then to help that company identify the opportunity and assist them through evaluation and licensing,” he added.
TechLink’s licensing experts and business advocates “help private companies evaluate and license VA inventions, sort of like a matchmaker,” Bloomer said.
TechLink and the VA Technology Transfer program have been helping companies take VA technology to market for the benefit of both veterans and the general public since 1999.
The two groups “work collaboratively to bring the medical industry’s attention to the scientific achievements of the VA and VA-funded researchers who are consistently inventing novel medical devices, detection technologies and therapies,” Bloomer added. “The VA’s patent portfolio contains many opportunities for companies to expand in the healthcare field.”
-
Hewes D, Tatomir A, Kruszewski AM, Rao G, Tegla CA, Ciriello J, Nguyen V, Royal W 3rd, Bever C, Rus V, Rus H. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis. Exp Mol Pathol. 2017 Apr;102(2):191-197.
-
Kruszewski AM, Rao G, Tatomir A, Hewes D, Tegla CA, Cudrici CD, Nguyen V, Royal W 3rd, Bever CT Jr, Rus V, Rus H. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Exp Mol Pathol. 2015 Dec;99(3):498-505.
